Interaction of oxaliplatin, cisplatin, and carboplatin with hemoglobin and the resulting release of a heme group

Chemical Research in Toxicology

Volumn 17, Issue 10, 2004, Pages 1391-1397

  Mandal, Rupasri ^a   Kalke, Robyn ^a   Li, Xing Fang ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; HEME DERIVATIVE; HEMOGLOBIN; IRON; OXALIPLATIN; PLATINUM DERIVATIVE;

ARTICLE; BLOOD SAMPLING; CELL DEATH; CHROMATOGRAPHY; COMPLEX FORMATION; CONTROLLED STUDY; DISSOCIATION; DNA ADDUCT; DRUG ACTIVITY; DRUG PROTEIN BINDING; ENZYME RELEASE; ERYTHROCYTE; HUMAN; HUMAN CELL; MASS SPECTROMETRY; PROTEIN ADDUCT; ROOM TEMPERATURE; TOXICITY; VOLUNTEER;

BINDING, COMPETITIVE; CARBOPLATIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CISPLATIN; ERYTHROCYTES; HEME; HEMOGLOBINS; NANOTECHNOLOGY; ORGANOPLATINUM COMPOUNDS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TIME FACTORS;

EID: 6344250910     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx049868j     Document Type: Article

References (33)

1. Rosenberg, B. (1999) In Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug (Lippert, B., Ed.), Part 4, p 3, Verlag Helvetica Chimica Acta, Zurich.
2. Roberts, J. J., Van der Vijgh, W. J. F., Vermorken, J. B., and Douple, E. B. (1984) In Cancer Chemotherapy Annual (Pinedo, H. M., and Chabner, B. A., Eds.), p 118, Elsevier, Amsterdam.
3. Wiltshaw, E., and Kroner, T. (1976) Phase II study of cis-dichlorodiammineplatinum (II) (NSC-119875) in advanced adenocarcinoma of the ovary. Cancer Treat. Rep. 60, 55-60.
4. Rossof, A. H., Slayton, R. E., and Perlia, C. P. (1972) Preliminary clinical experience with cis-diamminedichloroplatinum (II) (NSC 119875, CACP). Cancer 30, 1451-1456.
5. Rose, W. C., and Schurig, J. E. (1985) Preclinical antitumor and toxicologic profile of carboplatin. Cancer Treat. Rev. 12 (Suppl. A), 1-19.
6. Harrap, K. R. (1985) Preclinical studies identifying carboplatin as a viable cisplatin alternative. Cancer Treat. Rev. 12 (Suppl. A), 21-33.
7. Harrap, K. R., Jones, M., Wilkinson, C. R., Clink, H. M., and Sparrow, S. (1980) In Cisplatin: Current Status New Development [Pap. Symp.], p 193, Academic Press, New York.
8. Calvert, A. H., Newell, D. R., Gumbrell, L. A., O'Reilly, S., Burnell, M., Boxall, F. E., Siddik, Z. H., Judson, I. R., Gore, M. E., and Wiltshaw, E. (1989) Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J. Clin. Oncol. 7, 1748-1756.
9. Kjorstad, K., Harris, A., Bertelsen, K., Slevin, M., Schultz, H., Hellman, K., Janssens, N., Martin, A., and Canetta, R. (1992) A multicenter phase-II study Of carboplatin in advanced ovarian-carcinoma-final report. Ann. Oncol. 3, 217-222.
10. Connors, T. A., Jones, M., Ross, W. C. J., Braddock, P. D., Khokhar, A. R., and Tobel, M. L. (1972) New platinum complexes with antitumor activity. Chem.-Biol. Interact. 5, 415-424.
11. Burchenal, J. H., Kalaher, K., Dew, K., Lokys, L., and Gale, G. (1978) Studies of cross-resistance, syuergistic combinations and blocking of activity of platinum derivatives. Biochimie 60, 961-965.
12. Cvitkovic, E. (1998) A historical perspective on oxaliplatin: Rethinking the role of platinum compounds and learning from near misses. Semin. Oncol. 25, 1-3.
13. Cvitkovic, E. (1998) Ongoing and unsaid on oxaliplatin: The hope. Br. J. Cancer Suppl. 4 (77), 8-11.
14. Dunn, T. A., Schmoll, H. J., Grunwald, V., Bokemeyer, C., and Casper, J. (1997) Comparative cytotoxicity of oxaliplatin and cisplatin in nonseminomatous germ cell cancer cell lines. Invest. New Drugs 15, 109-114.
15. Soulie, P., Bensmaine, A., Garrino, C., Chollet, P., Brain, E., Fereres, M., Jasmin, C., Musset, M., Misset, J. L., and Cvitkovic, E. (1997) Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer. Eur. J. Cancer 33, 1400-1406.
16. Gamelin, E., Bouil, A. L., Boisdron-Celle, M., Turncant, A., Delva, R., Cailleux, A., Krikorian, A., Brienza, S., Cvitkovic, E., Robert, J., and Allain, P. (1997) Cumulative pharmacokinetic study of oxaliplatin, administered every three weeks, combined with 5-flurouracil in colorectal cancer patients. Clin. Cancer Res. 3, 891-899.
17. O'dwyer, P. J., Stevenson, J. P., and Johnson, S. W. (2000) Clinical pharmacokinetics and administration of established platinum drugs. Drugs 59 (Suppl. 4), 19-27.
18. Louvet, C., Andre, T., Tigaud, J. M., Gamelin, E., Douillard, J. Y., Brunet, R., Francois, E., Jacob, J. H., Levoir, D., Taamma, A., Rougier, P., Cvitkovic, E., and de Gramont, A. (2002) Phase II study of oxaliplatin, fluorouracil and folinic acid in locally advanced or metastatic gastric cancer patients. J. Clin. Oncol. 20, 4543-4548.
19. Kern, W., Beckert, B., Lang, N., Stemmler, J., Beykirch, M., Stein, J., Goecke, E., Waggershauser, T., Braess, J., Schalhorn, A., and Hiddemann, W. (2001) Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-flurouracil in patients with hepatic metastases from colorectal cancer. Ann. Oncol. 12, 599-603.
20. Eastman, A. (1982) Separation and characterization of products resulting from the reaction of cis-diamminedichloroplatinum(II) with deoxyribonucleosides. Biochemistry 21, 6732-6736.
21. Jamieson, E. R., and Lippard, S. J. (1999) Structure, recognition, and processing of cisplatin-DNA adducts. Chem. Rev. 99, 2467-2498.
22. Go, R. S., and Adjei, A. A. (1999) Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J. Clin. Oncol. 17, 409-422.
23. Espinosa, E., Feliu, J., Zamora, P., Gonzalez Baron, M., Sanchez, J. J., Ordonez, A., and Espinosa, J. (1995) Serum albumin and other prognostic factors related to response and survival in patients with advanced nonsmall cell lung cancer. J. Lung Cancer 12, 67-76.
24. Mandal, R., Teixeira, C., and Li, X.-F. (2003) Studies of cisplatin and hemoglobin interactions using nanospray mass spectrometry and liquidchromatography with inductively coupled plasma mass spectrometry. Analyst 128, 629-634.
25. Mandal, R., Jiang, G., and Li, X.-F. (2003) Direct evidence for co-binding of cisplatin and cadmium to a native zinc- and cadmium-containing metallothionein. Appl. Organomet. Chem. 17, 675-681.
26. Mandal, R., Kalke, R., and Li, X.-F. (2003) Mass spectrometric studies of cisplatin-induced changes of hemoglobin. Rapid Commun. Mass Spectrom. 17, 2748-2754.
27. Albert, S. N., Jain, S. C., Shibuya, J., and Albert, C. A. (1965) The Hematocrit in Clinical Practice, Chapter 1, Charles C. Thomas Publisher, Springfield, IL.
28. Gullo, J. J., Litterst, C. L., Maguire, P. J., Sikic, B. I., Hoth, D. F., and Wolley, P. V. (1980) Pharmacokinetics and protein binding of cis-dichlorodiammine platinum(II) administered as a 1 h or as a twenty hour infusion. Cancer Chemother. Pharmacol. 5, 21-26.
29. Boisdron-Celle, M., Lebouil, A., Allain, P., and Gamelin, E. (2001) Pharmacokinetic properties of platinium derivatices. Bull. Cancer 88, S14-S19.
30. Pendyala, L., and Creaven, P. J. (1993) In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res. 53, 5970-5976.
31. Kung, A., Strickmann, D. B., Galanski, M., and Keppler, B. K. (2001) Comparison of the binding behavior of oxaliplatin, cisplatin and analogues to 5′-GMP in the presence of sulfur-containing molecules by means of capillary electrophoresis and electrospray mass spectrometry. J. Inorg. Biochem. 86, 691-698.
32. Burtis, C. A., and Ashwood, E. R., Eds. (1994) Tietz Textbook of Clinical Chemistry, 2nd ed., p 2021, W. B. Daunders Company, Philadelphia, PA.
33. Levi, F., Metzger, G., Massari, C., and Milano, G. (2000) Oxaliplatin: Pharmacokinetics and chronopharmacological aspects. Clin. Pharmacokinet. 38, 1-21.